Top 10 Drug Discovery and Development Consulting/Services Companies in Europe - 2019
pharmatechoutlook
Origenis: A NEW APPROACH TO SMALL MOLECULE DRUG DISCOVERY

Top 10 Drug Discovery and Development Consulting/Services Companies in Europe - 2019

In the pharmaceutical industry, the process of developing nascent drugs to cure a disease is quite long, costly, and at the same time uncertain. In light of this, many experts in this space cite that the costs of developing new drugs can be reduced by the use of new technologies and with a deep understanding of biology. Albeit the objectives of drug delivery remain the same, the methods and techniques used in drug development continue to experience radical changes. In a nutshell, the standard approach to drug discovery is to identify a single molecular disease target and subsequently identify a compound that interacts and modulates with high specificity. Today, majority of the innovation reinvigorating the drug development methodologies seeks to access and integrate more information – about targets, compounds, and disease phenotypes. Next, the increasing size of chemical libraries and high throughput screening (HTS) technologies have enabled thousands or millions of compounds to be screened and the concomitant increase in compounds have supplemented the urgency for the bioanalysis of metabolites, and a need for faster turnaround.

To assist CIOs maneuver in the right direction while working on Drug Discovery and Development, a distinguished panel of CEOs, CIOs, VCs, and analysts along with the Pharma Tech Outlook’s editorial board has selected the leading Drug Discovery and Development service providers in Europe. The companies featured in this edition demonstrate an ability to develop innovative technologies combined with outstanding customer service.

We present to you Top 10 Drug Discovery and Development Consulting/Services Companies in Europe - 2019.

Top Drug Discovery and Development Europe Companies

Provides state-of-the-art tech-stack to unlock the truth of cosmetic active ingredients and pharmaceutical drug candidates to accelerate the speed-to-market process

genel.fr

The company provides ANCHOR, an autofluorescence technology for rapid and efficient viral vector imaging and antiviral discovery

neovirtech.com

Clarity Genomics

Clarity Genomics

Clarity Genomics uses advanced algorithms and machine learning to analyze host-microbiome data and provide valuable interpretations for clinical research. The company works closely with their clients to offer biological insights that empower the development of new microbiome products and therapies. Partnerships with leading research institutions ensure that the project receives relevant information utilizing technologies and techniques on the forefront of innovation. It paves the way for integrated human host-microbiome data analysis in clinical research

Euretos

Euretos

Founded in 2012, Netherlands-based Euretos provides an AI platform for the pre & early-clinical researchers to discover in-silico and validate targets and biomarkers. The platform enables a systems biology approach where researchers discover how x-omics molecular mechanisms influence cell and tissue functions, and in turn mediate phenotypes and disease pathology. The company supports clients through AI/systems biology driven research consulting, involving cutting edge approaches such as machine learning; direct access to the cloud based Euretos discovery platform via user friendly application; API Integration of the discovery platform in a company’s IT environment/workflows; integration of company proprietary data and public data in a secure environment. By integrating over 250 different public databases, the platform provides the largest single environment in which the latest multi omics data is interlinked to literature, experimental and clinical evidence. Euretos gives the power of AI and ‘big data’ analytics in the hands of the researcher via an intuitive search engine, easy to use analytics functions and embedded workflows tailored for specific research questions. The data integrated in the platform include genetic, genomic and proteomic annotations, expression profiles, experimental and animal models, diseases, phenotypes, pathways, small molecules - covering metabolites, food ingredients, as well as therapeutic agents (antibodies and peptides). Company proprietary data can be integrated into the platform for even more optimal results and hosted in a secure cloud environment or installed on-site

GENEWIZ

GENEWIZ

Headquartered in South Plainfield, NJ, GENEWIZ is a privately-held global enterprise with locations across the globe. GENEWIZ is a leading global genomics service company. A full-service provider, GENEWIZ provides DNA sequencing, gene synthesis, molecular biology, next generation sequencing, bioinformatics, and GLP regulatory and clinical services. From the company’s founding, GENEWIZ has maintained its unwavering commitment to providing customers with the best value. Excelling in both science and customer support, GENEWIZ is dedicated to accelerating scientific discovery, as well as to developing and delivering innovative solutions for translational medicine and healthcare. Easily accessible around the world, GENEWIZ is the preferred partner at leading academic, pharmaceutical, biotechnology, agricultural, government, and clinical institutions. The company aims to contribute to the advancement of life sciences and technologies. Together with clients, GENEWIZ can make a difference in the pursuit of scientific discoveries, better healthcare, a greener environment, and abundant food supplies. The goal of GENEWIZ is to be the best in the world and the best for the world

IRBM

IRBM

IRBM is committed to accelerating discovery and preclinical development of drug candidates. Initially a Merck Research Laboratories site, the company got reorganized into an independent company in 2009, retaining the core scientific leadership and team that developed 4 drugs now on the market. In the highly competitive landscape of R&D, IRBM's professional team strongly believes in the value of assigning highly experienced scientists to client's research projects. The company has built several successful collaborations with global industry leaders. These partners strongly benefit from the extensive experience of IRBM's core team in preclinical drug discovery and development activities, particularly on small molecules and peptide therapeutics. Through integrated drug discovery projects carried out entirely in IRBM's facility, this company acts as an auxiliary R&D hub for the partners’ research. IRBM team’s expertise in integrated drug discovery projects is applicable to any therapeutic area, and the company also provides additional scientific support and know-how for the development of compounds in highly competitive fields such as infectious diseases, neurode generation and oncology. The company has facilities in Milan and Rome, supported by in-house HTS and NMR units, strong medicinal chemistry and peptide chemistry groups, a very experienced DMPK group, CADD, in vitro biology, a proprietary phage library, and an in house cGMP CMO facility currently focused on experimental adenoviral vaccine production. IRBM's results in delivering 4 marketed drugs and more than 25 preclinical candidates are supported by more than 800 published papers and more than 100 patents

Metabolon

Metabolon

Metabolon provides actionable insights to answer some of biology’s most difficult questions for researchers and clinicians. Its Precision Metabolomics™ is a powerful tool for assessing health and is delivering biomarker discoveries, innovative diagnostic tests, and ground-breaking data in genomics and population health initiatives. Metabolon’s expertise is also accelerating research and product development for clients across academia and the pharmaceutical, biotechnology, consumer products, agriculture and nutrition industries. Metabolon has conducted more than 10,000 independent and collaborative studies, resulting in 1,000+ publications

Neox Clinical Research

Neox Clinical Research

Neox conducts clinical trials for pharamaceutical, biotechnology, medical device companies, and other CRO's throughout Europe with a focus on central and eastern Europe. The company was established in 2004 and since then have conducted hundreds of studies covering all major therapeutic areas with an emphasis on Oncology, Cardiology and the CNS. Neox offers clinical research services such as: biostatistics, clinical monitoring, data management, eCRF design, eDiaries, expert consultancy, drug safety, medical monitoring, medical writing, pharmacovigilance and safety, project management, quality assurance & audits, regulatory and ethics committee submissions, site contracting, study rescue and training & education, for Phase I-IV studies. This privately owned company offers services as a full-service package or induvidually as a tailored solution for specific needs

Oncodesign

Oncodesign

Working alongside big pharma, biotech’s, public research institutions and investment groups, Oncodesign orients the research and development of new therapeutic and diagnostic tools. Technological innovation lies at the heart of Oncodesign’s model—the Etiology, Discovery and Experimentation activities designed and implemented by Oncodesign contribute to a more effective approach to the phenomenon of innate and acquired resistance, more effective treatments and a reduction in therapeutic failures. Oncodesign can predict and identify, at a very early stage, each molecule's therapeutic usefulness and potential to become an effective drug

Pharmetheus

Pharmetheus

Pharmetheus offers pharmacometric services supporting drug development of compounds in all phases and in all therapeutic areas. Pharmetheus offers strategic advice and hands-on analyses across all different phases, in order to support clients in drug development decisions. The company has extensive experience in PK and PK/PD analysis to support regulatory interactions across the product life cycle: pre-submission, during submission and in the post-authorization phase. Pharmetheus offers physiologically based pharmacokinetic (PBPK) modeling and simulation across all phases of drug development. PBPK enables a mechanistic bottom-up modeling and simulation approach for prediction, translation and analysis of pre-clinical and clinical data